April 27, 2012


Strong performance in Q1 2012 including Genzyme contribution

 


Strong performance in Q1 2012 including Genzyme contribution

Commenting on the Group’s performance in Q1 2012, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “During the first quarter, our Business EPS grew by 7.2%2. This strong performance was driven by Genzyme, our growth platforms3, and cost savings. This quarter also reflects the production recovery of Genzyme with the first shipment of Fabrazyme® produced in Framingham in March. In addition, we have submitted three new products to regulatory authorities, and released impressive clinical results for our anti-PCSK9 agent and for LemtradaTM at recent medical congresses. Although as expected, Plavix ® will lose exclusivity in May in the U.S., the strong underlying performance of the business is consistent with our medium term growth outlook”.